


THERAPIES

TO STANDARD OF CARE?

FROM BREAKTHROUGH INNOVATION

CAR-T CELL



CAR-T Cell Therapies: A new hope for cancer treatment

CAR-T cell therapies are in the spotlight for their:



Targeted action: Specifically destroying cancer cells



Personalized approach: Leveraging the patient's own T cells



Breakthrough results: Offering hope for sustained remission in resistant cancers




Current indications approved for CAR-T cell therapies in EU and the US

| Indications | Therapy lines | | | Product with |
|--|----------------------|----------------------|----------------------|--------------------------|
| | 1 st line | 2 nd line | 3 rd line | earliest therapy line |
| <u>Pediatric</u> acute lymphoblastic leukemia (ALL) | | | $ \Longrightarrow $ | KYMRIAH |
| <u>Adult</u> acute lymphoblastic leukemia (ALL) | | | | TECARTUS |
| Diffuse large B-cell lymphoma (DLBCL) | | | | |
| High Grade B-cell lymphoma (HGBCL) | | | | |
| Primary mediastinal large B-cell lymphoma (PMBCL) | | | | Breyanzi |
| Follicular lymphoma (FL) | | Grade 3B | All others | Breyanzi |
| Mantle cell lymphoma (MCL) | | | \rightarrow | TECARTUS |
| Multiple myeloma (MM) | | | | CARVYKTI |

Sources: European Medicines Agency, U.S. Food and Drug Administration

Advention

Drivers that will shape the future of the CAR-T cell therapy ecosystem



Advention

Learn more by requesting a copy of our white paper today!

Or contact us:

frederic.misse@adventionbp.com gonzague.godinot@adventionbp.com steven.ries@adventionbp.com

Advention